Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Bay 65-1942 (hydrochloride)

Catalog No: tcsc0623

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Specifications

CAS No:
600734-06-3

Formula:
$C_{22}H_{26}ClN_3O_4$

Pathway:
NF-κB

Target:
IKK

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
431.91

Product Description

Bay 65-1942 hydrochloride is an ATP-competitive and selective **IKKβ** inhibitor.

IC50 & Target: IKKβ[1]

In Vitro:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Delivery of Bay 65-1942 prior to ischemia significantly decreases left ventricular infarct size compared with animals receiving vehicle. Compared with sham animals, animals receiving vehicle have a significant increase in the infarct-to-area at risk (AAR) ratio (70.7±3.4 vs. 5.8±3.4%, P[1].

In Vivo: Inhibitors of MEK (AZD6244) and IKK (BAY 65-1942) are used at their IC_{50} concentrations, as determined by a 48 hour MTS assay, which achieve sufficient inhibition of kinase activity. MYL-R cells are treated for 24 hours with AZD6244 (5 μM), BAY 65-1942 (10 μM), or a combination of these inhibitors at the same concentrations. AZD6244 and BAY 65-1942 demonstrate synergistic inhibition of cell viability at the dose combination (5 μM AZD6244+10 μM BAY 65-1942), which correlates with IC_{75} (CI = 0.48±0.01). Synergism is also indicated at the IC_{50} (CI = 0.56±0.09) and IC_{90} (CI = 0.46±0.02) dose combinations reported by the software (CI values are the mean of three independent experiments, ± standard deviation). AZD6244 and BAY 65-1942 treatment induces 2- and 1.3-fold caspase 3/7 activation, respectively, compared to the DMSO-treated cells. Treatment with a combination of AZD6244 plus BAY 65-1942 leads to a 3.2-fold increase in caspase 3/7 activity[2].